{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:28:24Z","timestamp":1792218504150,"version":"4.4.0"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T00:00:00Z","timestamp":1648080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Rash eruptions are a common side-effect of pemetrexed, for which the administration of 8\u00a0mg\/day of dexamethasone for 3 days from the day preceding pemetrexed administration is recommended. This study aimed to prospectively assess the effectiveness of prophylactic administration of low-dose dexamethasone for pemetrexed-induced rashes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This single-arm, phase II study recruited patients with non-squamous non\u2013small cell lung cancer and malignant pleural mesothelioma scheduled to receive chemotherapy including pemetrexed. Patients received 2\u00a0mg of dexamethasone daily from days 2 to 6 after chemotherapy with pemetrexed. The primary endpoint was the 3-week incidence of rash eruptions.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Twenty-five patients were enrolled between September 2017 and May 2019. The incidence of rash after 3 weeks was 16.7%. Rashes erupted mainly on the upper half of the body, such as the chest and neck, and were of grades 1 and 2 in 2 patients each. No rashes of grade 3 or higher were observed, and there were no adverse events associated with additional corticosteroids.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Prophylactic administration of low-dose dexamethasone for 5 days from the day after pemetrexed administration resulted in a milder incidence and severity of rash. These findings may provide a standard preventative strategy for pemetrexed-induced rashes. (Trial identifier: UMIN000025666).<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyab077","type":"journal-article","created":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T12:08:49Z","timestamp":1641298129000},"page":"e554-e560","source":"Crossref","is-referenced-by-count":5,"title":["Prevention of Pemetrexed-Induced Rash Using Low-Dose Corticosteroids: A Phase II Study"],"prefix":"10.1093","volume":"27","author":[{"given":"Takumi","family":"Sakurada","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Tokushima University Hospital , Tokushima , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Nokihara","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Rheumatology, Tokushima University Graduate School of Biomedical Sciences , Tokushima , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Koga","sequence":"additional","affiliation":[{"name":"Clinical Research Professionals, Clinical Study Support, Inc. , Nagoya , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Zamami","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Okayama University Hospital , Okayama , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Goda","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tokushima University Hospital , Tokushima , Japan"},{"name":"Department of Clinical Pharmacology and Therapeutics, Tokushima University Graduate School of Biomedical Sciences , Tokushima , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Yagi","sequence":"additional","affiliation":[{"name":"Clinical Trial Center for Developmental Therapeutics, Tokushima University Hospital , Tokushima , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Hamano","sequence":"additional","affiliation":[{"name":"Clinical Trial Center for Developmental Therapeutics, Tokushima University Hospital , Tokushima , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuka","family":"Aizawa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tokushima University Hospital , Tokushima , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Ogino","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Rheumatology, Tokushima University Graduate School of Biomedical Sciences , Tokushima , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seidai","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Rheumatology, Tokushima University Graduate School of Biomedical Sciences , Tokushima , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Kirino","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tokushima University Hospital , Tokushima , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisatsugu","family":"Goto","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Rheumatology, Tokushima University Graduate School of Biomedical Sciences , Tokushima , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Nishioka","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Rheumatology, Tokushima University Graduate School of Biomedical Sciences , Tokushima , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Ishizawa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tokushima University Hospital , Tokushima , Japan"},{"name":"Department of Clinical Pharmacology and Therapeutics, Tokushima University Graduate School of Biomedical Sciences , Tokushima , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,3,24]]},"reference":[{"key":"2022070520264114900_CIT0001","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1200\/JCO.1999.17.4.1194","article-title":"Multitargeted antifolate ly231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group.","volume":"17","author":"Rusthoven","year":"1999","journal-title":"J Clin Oncol"},{"key":"2022070520264114900_CIT0002","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","article-title":"Randomized phase iii trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.","volume":"22","author":"Hanna","year":"2004","journal-title":"J Clin Oncol"},{"key":"2022070520264114900_CIT0003","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","article-title":"Phase iii study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.","volume":"26","author":"Scagliotti","year":"2008","journal-title":"J Clin Oncol"},{"key":"2022070520264114900_CIT0004","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/jjco\/hyn024","article-title":"Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: a phase I\/II study in Japanese patients.","volume":"38","author":"Nakagawa","year":"2008","journal-title":"Jpn J Clin Oncol"},{"key":"2022070520264114900_CIT0005","doi-asserted-by":"crossref","first-page":"4206","DOI":"10.1158\/1078-0432.CCR-07-5143","article-title":"Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin b12 in previously treated patients with non-small cell lung cancer.","volume":"14","author":"Ohe","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2022070520264114900_CIT0006","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1023\/A:1008372529239","article-title":"Phase ii study of first-line ly231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: an NCIC Clinical Trials Group Study.","volume":"10","author":"Cripps","year":"1999","journal-title":"Ann Oncol"},{"key":"2022070520264114900_CIT0007","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1248\/bpb.b15-00435","article-title":"Pemetrexed-induced rash may be prevented by supplementary corticosteroids.","volume":"38","author":"Sakurada","year":"2015","journal-title":"Biol Pharm Bull"},{"key":"2022070520264114900_CIT0008","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/sj.bjc.6603321","article-title":"A phase I study of pemetrexed (ly231514) supplemented with folate and vitamin b12 in japanese patients with solid tumours.","volume":"95","author":"Nakagawa","year":"2006","journal-title":"Br J Cancer"},{"key":"2022070520264114900_CIT0009","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer.","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"2022070520264114900_CIT0010","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, pd-l1-expressing, locally advanced or metastatic non-small-cell lung cancer (keynote-042): a randomised, open-label, controlled, phase 3 trial.","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"2022070520264114900_CIT0011","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1111\/cas.14817","article-title":"Impower132: Atezolizumab plus platinum-based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients.","volume":"112","author":"Nishio","year":"2021","journal-title":"Cancer Sci"},{"key":"2022070520264114900_CIT0012","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer.","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"2022070520264114900_CIT0013","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer.","volume":"36","author":"Arbour","year":"2018","journal-title":"J Clin Oncol"},{"key":"2022070520264114900_CIT0014","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028662","article-title":"Cancer inflammation and cytokines.","volume":"10","author":"Galdiero","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2022070520264114900_CIT0015","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0140-6736(00)04046-0","article-title":"Inflammation and cancer: back to virchow?","volume":"357","author":"Balkwill","year":"2001","journal-title":"Lancet"},{"key":"2022070520264114900_CIT0016","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1089\/aid.2012.0180","article-title":"The design of single-arm clinical trials of combination antiretroviral regimens for treatment-naive HIV-infected patients.","volume":"29","author":"Zheng","year":"2013","journal-title":"AIDS Res Hum Retroviruses"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/7\/e554\/44418299\/oyab077.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/7\/e554\/44418299\/oyab077.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T20:26:59Z","timestamp":1657052819000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/27\/7\/e554\/6553833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,24]]},"references-count":16,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,3,24]]},"published-print":{"date-parts":[[2022,7,5]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyab077","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7,1]]},"published":{"date-parts":[[2022,3,24]]}}}